Study in Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics Between Early- and Late-Onset Pancreatic Neuroendocrine Tumors: A Multicenter Retrospective Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 600
- 试验地点
- 2
- 主要终点
- Overall Survival
研究概览
简要总结
The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine tumors (EO-PanNETs) and late-onset pancreatic neuroendocrine tumors (LO-PanNETs).
The main questions it aims to answer are:
Are there distinct clinical, pathological, and metabolic profiles in EO-PanNETs compared with LO-PanNETs? Do EO-PanNETs have different prognostic outcomes compared with LO-PanNETs? Researchers will compare EO-PanNET patients with LO-PanNET patients and with matched nonmalignant controls to assess differences in tumor characteristics and associated metabolic conditions.
Participants will:
Provide retrospective clinical, pathological, and metabolic data from hospital records.
Have survival and recurrence outcomes assessed through follow-up data review.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years or older; histopathologically confirmed pancreatic neuroendocrine tumor by surgical resection or biopsy.
排除标准
- •Pancreatic neuroendocrine carcinoma; incomplete pathological data; received antitumor treatment prior to presentation; with other malignanies or malignant history.
研究组 & 干预措施
Early-onset pancreatic neuroendocrine tumors group
This group comprises patients diagnosed with pancreatic neuroendocrine tumors before the age of 50 years. All cases were histopathologically confirmed and treated at one of the participating centers.
Late-onset pancreatic neuroendocrine tumors group
This group comprises patients diagnosed with pancreatic neuroendocrine tumors at or after the age of 50 years. All cases were histopathologically confirmed and treated at one of the participating centers.
结局指标
主要结局
Overall Survival
时间窗: From date of randomization until the date of death from any cause or the date of the last follow-up, whichever came first, assessed up to 12 years
次要结局
- Disease-specific survival(From date of diagnosis until death due to PanNETs, up to 12 years)
- Progression-free survival(From date of diagnosis until the date of disease recurrence or death from any cause, whichever came first, assessed up to 12 years.)
- Disease-free survival(From date of surgery until first documented recurrence, metastasis, or death from any cause, assessed up to 12 years.)
研究者
Hanxiang Zhan
Chief Physician, Department of Pancreatic Surgery
Qilu Hospital of Shandong University